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weekly cost exceeded $50 were more likely to discontinue than
patients with lower costs (HR 1.59, P < 0.001). CONCLUSION:
The majority of patients have very reasonable OOP for biolog-
ics. However, a small number of patients are burdened with high
OOP costs. The adverse impact of high OOP on adherence and
persistence needs to be considered when making decisions about
increasing co-pays.
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OBJECTIVES: Rheumatoid Arthritis (RA) imposes a signiﬁcant
burden of disease to both affected patients and the society as a
whole. We performed the ﬁrst German claims database analysis
among members of a statutory health insurance fund to estimate
RA treatment prevalence, to describe prescription patterns and
assess overall disease burden. METHODS: We based our analy-
sis on billing data from the years 2000 to 2004 of a German
sickness fund covering 1.5 million beneﬁciaries. RA patients
were identiﬁed by either inpatient or sick leave records due to
ICD-10 codes (M05, M06) or at least two prescriptions of a
disease-modifying drug (DMARD) or a TNF-α inhibitor. We
excluded patients with a variety of co-medications and diag-
noses, e.g. Psoriasis, Crohn’s Disease and malignant disease. We
speciﬁed treatment prevalence and patterns of RA disease man-
agement with DMARDs and TNFs in the selected population.
RESULTS: Out of the 728,111 beneﬁciaries continuously
enrolled between 2000 and 2004 n = 5850 (mean age: 43 ± 14
years) fulﬁlled the inclusion criteria for RA. RA treatment preva-
lence, standardized to the general German population was
0.68% for men and 1.25% for women. 43% of the patients with
RA were treated with DMARDs and 3.2% received TNF-α
inhibitors. 26% of RA-patients were initiated on DMARD
therapy by a general practitioner. Compared to the RA popula-
tion as a whole patients receiving TNF-α inhibitors were char-
acterized by a 2.6 fold number of sick leaves and a 6.4 fold
number of hospitalizations in the year prior to therapy initiation.
CONCLUSION: The RA treatment prevalence found in this
study is in line with local epidemiological research. As less than
half of RA-patients had a prescription of a DMARD, this may
indicate that therapeutic standards are not met. TNF-α inhibitors
are mainly prescribed in a high burden RA subpopulation.
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OBJECTIVES: The purpose of this study was to evaluate the
impact of specialty pharmacy prior authorization (SPA) program
on prescription costs for the biologic response modiﬁers
(Amevive, Enbrel, Humira, Kineret, Raptiva, and Remicade)—a
new class of medication for the treatment of several disease states
such as Rheumatoid Arthritis. METHODS: Prescription data
were obtained from a pharmacy beneﬁt manager’s pharmacy
claims database. This study used a retrospective case-control
one-to-one matching approach based on patient age, gender, and
client characteristics including the number of eligible members,
client type and region. The case clients had enrolled in the SPA
program in January 2005 and had remained part of the program
by December 31, 2005. Clients whose members did not use the
biologic response modiﬁers were excluded from the study. Per
eligible member per month (PMPM) total costs was the outcome
measured. RESULTS: The average PMPM total, plan and
member costs were $1.33, $1.30, and $0.03 in the case group,
while the average PMPM total, plan and member costs were
$1.51, $1.47 and $0.04 in the control group. Clients who imple-
mented a specialty pharmacy prior authorization program for
the biologic response modiﬁers saved an estimated PMPM total
cost of $0.18. CONCLUSION: Implementing a specialty phar-
macy prior authorization program reduced prescription drug
costs for the biologic response modiﬁers.
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OBJECTIVES: A major component of the economic burden
associated with the treatment of arthritis relates to surgical joint
replacement of the hips or knees. The objective of this study is
to compare the burden of hip/knee replacements performed in
the U.S. in the year 2000 and 2004. METHODS: The Health
care Cost and Utilization Project—National Inpatient Survey”
(HCUP-NIS) was analyzed to estimate the changes in the burden
of hip and knee replacements in the U.S. The HCUP itself is a
compilation of billing data which can yield estimates of national
hospital charges as well as the total number of hip and knee
replacement procedures. In 2004, the HCUP-NIS database con-
tained nearly 8 million records from about 1000 hospitals. The
ICD-9-CM procedure codes used in identifying patients are
81.51 (total hip replacement) and 81.54 (Total/partial knee
replacement). RESULTS: In the year 2004, approximately
225,900 total hip replacement and 431,458 total knee replace-
ment procedures were performed in the U.S. This is a 37%
increase in hip replacement procedures and a 53% increase in
total knee replacements compared to the year 2000 (164,458
total hip replacement and 281,534 total knee replacement). In
terms of economic burden, the national bill of hospital charges
increased by 111% (from $10.8 billion in year 2000 to $22.9
billion in year 2004). CONCLUSION: The data shows a steep
increase in the burden of joint replacements. Not considering pre
and post-operation care, the estimated hospital charges for joint
replacements alone were nearly 22.9 billion dollars in the United
States during the year 2004. This data, however, does not
provide reasons of steep increase in the burden of joint replace-
ments during this four year period. Further study is needed to
address these issues.
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OBJECTIVES: The introduction of tumor necrosis factor (TNF)
inhibitors such as etanercept and inﬂiximab has represented a
critical advance in the available treatments for patients with
Ankylosing Spondylitis (AS). Several clinical studies have shown
superior efﬁcacy of TNF inhibitors, but high costs and infrequent
instances of serious adverse side effects ask for priority setting.
The aim of this review was to identify and summarize the phar-
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macoeconomic evidence of TNF inhibitors in AS and to provide
a critique of the methodology using Drummond’s 10-point
checklist. METHODS: A systematic literature search was con-
ducted by one researcher among publications in peer-reviewed
journals from January 2000 to April 2006 through electronic
databases (Medline, Embase, and Cochrane Database). Only
studies that provided economic evaluations of TNF inhibitors in
AS were included in the review. RESULTS: The search yielded a
total of eight cost studies. Only four met study inclusion crite-
ria. Three of the four studies were cost-effectiveness analysis and
two of the four compared etanercept and inﬂiximab in patients
with AS. The analytical time frame ranged from one year to 30
years. Costs and effects were appropriately discounted and 
sensitivity analysis was conducted to test the robustness of 
the model assumptions. Outcomes were presented as cost per
quality-adjusted life years (QALYs) or cost per Assessment in
Ankylosing Spondylitis Response Criteria. The incremental cost-
utility ratio of etanercept or inﬂiximab varied between US
$50,000–$250,000 per QALY when compared with usual care.
CONCLUSION: The costs per QALY ratios for the TNF
inhibitors seem to be a little higher than the normally accepted
societal thresholds ($50,000/QALY). The heterogeneity in the
cost-effectiveness results could be due to factors like patient
demographics, funding source and methodological variables.
Nonetheless, TNF inhibitors are a valuable treatment option and
further pharmacoeconomic analyses need be conducted to fully
evaluate their potential in patients with AS.
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OBJECTIVES: To assess the utilization patterns and costs for
health care services for chronic arthritis treatment among chil-
dren and adolescents enrolled in a state Medicaid program.
METHODS: A cross-sectional, descriptive analysis of a state
Medicaid administrative claims dataset was conducted. Medical
services claims with a primary diagnosis code for rheumatic dis-
eases (ICD-9-CM 696.0, 695.4, 710.X, 714.0, 714.2, 714.3X,
and 720.X) during calendar year 2003 for recipients under 21
years of age were extracted. Prescription medication claims were
extracted using de-identiﬁed unique recipient numbers obtained
from medical services claims. Prevalence and medical services use
rates were calculated by demographic categories. Costs were
reported from the perspective of Medicaid. RESULTS: There
were 171 children and adolescents who used medical services for
care of chronic arthritis, at an overall rate of 0.8/1000 recipi-
ents. The highest rates by demographic groups occurred among
females (1.0/1000), whites (0.9/1000), and recipients between
15–20 years of age (1.9/1000). Ofﬁce visits accounted for the
majority of medical services utilized (99%), at a rate of 3.4
visits/1000 recipients. Medicaid paid approximately $415/child
and adolescent recipient for chronic arthritis-related medical ser-
vices during the year. Dollars paid for ofﬁce visits accounted for
85% of the medical services costs at an average cost of $86 per
visit. A majority of the sample (63%) had a diagnosis for
rheumatoid arthritis (RA)/juvenile rheumatoid arthritis (JRA).
Among these children and adolescents, 62% had at least one pre-
scription claim for a narcotic analgesic, NSAID, oral steroid,
DMARD, or biologic agent at an average cost of $74/claim.
CONCLUSION: The prevalence and medical services utilization
patterns for chronic arthritis among children and adolescent
recipients in this State Medicaid population differed by demo-
graphic characteristics. Ofﬁce visits accounted for a majority of
medical services use and dollars. Most of the children and ado-
lescents with chronic arthritis had a diagnosis for RA/JRA.
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OBJECTIVES: Mixed treatment comparison is a generalisation
of meta-analysis. Instead of the same treatment for a disease
being tested in a number of studies, a number of different inter-
ventions are considered. Meta-regression is also a generalisation
of meta-analysis which explains the heterogeneity between the
treatment effects in the studies by regressing on study level
covariables. Our focus is where there are several different treat-
ments considered in a number of studies, and where differences
in efﬁcacy can be explained by differences in the study settings.
METHODS: We develop methods for simultaneously compar-
ing several treatments and adjusting for study level covariables
by combining ideas from mixed treatment comparisons and
meta-regression. We use a case study from rheumatoid arthritis.
We identiﬁed relevant trials of biologic verses standard therapy
or placebo and extracted the doses, comparators and patient
baseline characteristics. Efﬁcacy is measured using the log odds
ratio of achieving ACR50 responder status at 6 months. A
random-effects meta-regression model is ﬁtted which adjusts the
log odds ratio of an ACR50 response if treated with a biologic
therapy compared to placebo for study level prognostic factors.
The logit probability of a response is regressed onto a treatment
indicator and prognostic covariables. A different random effect
distribution on the log odds ratios is allowed for each different
treatment. This enables the odds ratio for each treatment to be
found as a function of the prognostic factors. RESULTS: The
apparent differences in the randomised trials between TNF
antagonists biologics are explained by differences in prognostic
factors and the analysis suggest that these drugs as a class are
not different from each other. CONCLUSION: We deﬁne a
methodology for combining meta-regression techniques with
ideas from mixed treatment comparisons. This allows different
treatments for the same condition to be compared whilst adjust-
ing for difference in the study populations.
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OBJECTIVES: To evaluate switching patterns among anti-TNFs
in rheumatoid arthritis (RA) patients. METHODS: A retrospec-
tive study utilizing the PharMetrics managed-care claims data-
base was conducted. The ﬁrst anti-TNF encounter among RA
patients between January 1, 2001 and January 1, 2004 was iden-
tiﬁed. Patients were required to have a minimum of 12-months
of continuous plan eligibility prior to and following their index
date. Three mutually exclusive cohorts were developed based on
their index biologic therapy (inﬂiximab, etanercept and adali-
mumab) plus methotrexate (MTX). The rates of switching and
